Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy

Immunological Investigations

Volumn 36, Issue 1, 2007, Pages 3-23

  Tonra, James R ^a,b   Hicklin, Daniel J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NONE   (United States)

Author keywords

Angiogenesis; Antivascular; Avastin; Targeted Therapy

Indexed keywords

2 C3; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL) PROPOXY]QUINAZOLINE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AG 13736; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CDP 791; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; IMC 1121B; MONOCLONAL ANTIBODY DC101; MV 833; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PAZOPANIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; SEMAXANIB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN TRAP; VATALANIB;

BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TARGETING; GLIOBLASTOMA; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG CARCINOMA; LUNG HEMORRHAGE; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; THROMBOSIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845892479     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130600991794     Document Type: Review

References (113)

1. Beecken, W. D. C., Fernandez, A., Joussen, A. M., Achilles, E. G., Flynn, E., Lo, K. M., Gillies, S. D., Javaherian, K., Folkman, J., Shing, Y. (2001). Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Can. Inst. 93:382-387.
2. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., Taraboletti, G. (1996). The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1843-1849.
3. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., Keshet, E. (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawl. J. Clin. Invest. 103:159-165.
4. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287-1295.
5. Blackwell, K. L., Haroon, Z. A., Shan, S., Saito, W., Broadwater, G., Greenberg, C. S., Dewhirst, M. W. (2000). Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin. Can. Res. 6:4359-4364.
6. Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., Ferrara, N. (1998). Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. The Prostate 35:1-10.
7. Borgstrom, P., Hillan, K. J., Sriramarao, P., Ferrara, N. (1996). Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 56:4032-4039.
8. Bos, R., van Diest, P. J., de Jong, J. S., van der Groep, P., van der Valk, P., van der Wall, E. (2005). Hypoxia-inducible factor-1α is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46:31-36.
9. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., Dewhirst, M. W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:941-943.
10. Browder, T., Butterfield, C. E., Draling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878-1886.
11. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger D. R., Connolly J. L., Schnitt S. J. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 26:86-91.
12. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., Senger, D. R. (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 143:1255-1262.
13. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., Dvorak, H. F. (1993). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:4727-4735.
14. Casanovas, O., Hicklin, D. J., Bergers, G., Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309.
15. Chung, K. Y, Saltz, L. B. (2005). Antibody-based therapies for colorectal cancer. Oncologist 10:701-709.
16. Ciardiello, F., Bianco, R., Damiano, V., Fontanini, G., Caputo, R., Pomatico, G., de Placido, S., Bianco, A. R., Mendelsohn, J., Tortora, G. (2000). Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6: 3739-3747.
17. Cobleigh, M. A., Langmuir, V. K., Sledge, G. W., Miller, K. D., Haney, L., Novotny, W. F., Reimann, J. D., Vassel, A. (2003). A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem. Oncol. 30:117-124.
18. Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L., Delfino, J. J., Siegel, N. R., Leimgruber, R. M., Feder, J. (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1470-1478.
19. Dvorak, H. F. (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:4368-4380.
20. Ellis, L. M., Takahashi, Y., Fenoglio, C. J., Cleary, K. R., Bucana, C. D., Evans, D. B. (1998). Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 34:337-340.
21. Erber, R., Hurnher, A., Katsen, A. D., Groth, G., Kerger, H., Hammes, H. P., Menger, M. D., Ullrich, A., Vajkoczy, P. (2004). Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340.
22. Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., Bukowski, R. M. (2005). Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Proceedings, Abstract Number 4510.
23. Escuin D., Kline E. R., Giannakakou P. (2005). Both microtubule- stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function. Cancer Res. 65:9021-9028.
24. Fenton B. M., Paoni S. F., Ding I. (2004). Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother. Oncol. 72:221-230.
25. Ferrara, N., Gerber, H. P., LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Med. 9:669-676.
26. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-1186.
27. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
28. Folkman, J., Merler, E., Abernathy, C., Williams, G. (1971). Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133:275-288.
29. Garcea, G., Lloyd, T. D., Gescher, A., Dennison, A. R., Steward, W. P., Berry, D. P. (2004). Angiogenesis of gastrointestinal tumors and their metastases - a target for intervention? Eur. J. Cancer 40:1302-1313.
30. Gerber, H. P., Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65:671-680.
31. Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., Benson, A. B. (2005). High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. 2005 ASCO Proceedings, Abstract Number 2.
32. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., Giaccia, A. J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91.
33. Gupta, K., Zhang, J. (2005). Angiogenesis: a curse or cure? Postgrad. Med. J. 81:236-242.
34. Hansen-Algenstaedt, N., Stoll, B. R., Padera, T. P., Dolmans, D. E., Hicklin, D. J., Fukumura, D., Jain, R. K. (2000). Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60:4556-4560.
35. Harris, A. (2002). Hypoxia- A key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47.
36. Hasan, J., Byers, R., Jayson, G. C. (2002). Intra-tumoural microvessel density in human solid tumors. Brit. J. Cancer 86:1566-1577.
37. Herbst, R. S., Johnson, D. H., Mininberg, E., Carbone, D. P., Henderson, T., Kim, E. S., Blumenschein Jr, G., Lee, J. J., Liu, D. D., Truong, M. T., Hong, W. K., Tran, H., Tsao, A., Xie, D., Ramies, D. A., Mass, R., Seshagiri, S., Eberhard, D. A., Kelley, S. K., Sandler, A. (2005). Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. 23:2544-2555.
38. Hess-Stumpp, H., Haberey, M., Thierauch K. H. (2005). PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochemistry 6:550-557.
39. Hicklin, D. J., Ellis, L. M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23:1011-1027.
40. Hockel, M., Schlenger, K., Hockel, S., Vaupel, P. (1999). Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59:4525-4528.
41. Hockel, M., Vaupel, P. (2001). Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Nat. Cancer. Inst. 93: 266-276.
42. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., Wiegand, S. J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998.
43. Hudis, C. A. (2005). Clinical implications of antiangiogenic therapies. Oncology 19:26-31.
44. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F. (2004). Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-2342.
45. Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., McDonald, D. M. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165:35-52.
46. Inoue, M., Hager, J. H., Ferrara, N., Gerber, H. P., Hanahan, D. (2002). VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1:193-202.
47. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
48. Jain, R. K., Baxter, L. T. (1988). Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 48:7022-7032.
49. Jayson, G. C., Mulatero, C., Ranson, M., Zweit, J., Jackson, A., Broughton, L., Wagstaff, J., Hakansson, L., Groenewegen, G., Lawrance, J., Tang, M., Wauk, L., Levitt, D., Marreaud, S., Lehmann, F. F., Herold, M., Zwierzina, H. (2002). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur. J. Cancer 41:555-563.
50. Johnson, D. H., Fehrenbacher L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore III, R. F., Gaudreault, J., Damico, L. A., Holmgren, E., Kabbinavar, F. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22:2184-2191.
51. Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., Novotny, W. F. (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 23:3697-3705.
52. Kabbinavar, F., Hurwitz H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., Bergsland, E. (2003). Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21:60-65.
53. Kamba, T., Tam, B. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso M., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., Anderson, K. D., Thurston, G., Joho, S., Springer, M. L., Kuo, C. J., McDonald, D. M. (2006). VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290:H560-H576.
54. Karayiannakis, A. J., Bolanaki, H., Syrigos, K. N., Asimakopoulos, B., Polychronidis, A., Anagnostoulis, S., Simopoulos, C. (2003). Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett. 194:119-124.
55. Kim, J. J., Tannock, I. F. (2005). Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat. Rev. Cancer 5:516-525.
56. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., Kerbel, R. S. (2000). Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24.
57. Kopec, J. A., Abrahamowicz, M., Esdaile, J. M. (1993). Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46:959-971.
58. Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., Plate, K. H. (2000). Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443.
59. Lamszus, K., Brockmann, M. A., Eckerich, C., Bohlen, P., May, C., Mangold, U., Fillbrandt, R., Westphal, M. (2005). Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. 11:4934-4940.
60. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., Boucher, Y. (2000). Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565-5570.
61. Lee, L., Sharma, S., Morgan, B., Allegrini, P., Schnell, C., Brueggen, J., Cozens, R., Horsfield, M., Guenther, C., Steward, W. P., Drevs, J., Leebwohl, D., Wood, J., McSheehy, P. M. (2005). Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol. 57:761-771.
62. Liang, W. C., Wu, X., Peale, F. V., Lee, C. V., Meng, G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H. P., Ferrara, N., Fuh, G. (2006). Cross-species VEGF-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281:951-961.
63. Lorincz, T., Toth, J., Szendroi, M., Timar, J. (2005). Microvascular density of breast cancer in bone metastasis: Influence of therapy. Anticancer Res. 25:3075-3082.
64. Lu, D., Shen, J., Vil M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., Zhu, Z. (2003). Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278:43496-43507.
65. Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J. A., Hooper, A., Priller, J., De Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, J. M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, H. F., Hicklin, D. J., Carmeliet, P. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med. 8:831-840.
66. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., Wu, Y., Hicklin, D., Zhu, Z., Hackett, N. R., Crystal, R. G., Moore, M. A. S., Hajjar, K. A., Manova, K., Benezra, R., Rafii, S. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7:1194-1201.
67. Magne, N., Marcy, P. Y., Chamorey, E., Guardiola, E., Pivot, X., Schneider, M., Demard, F., Bensadoun, R. J. (2001). Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: a long-term quality of life analysis. Head Neck 23:678-682.
68. Mandriota, S. J., Jussila, L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G., Orci, L., Alitalo, K., Christofori, G., Pepper, M. S. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO 20:672-682.
69. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N. P., Risau W., Ullrich A. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 26:835-846.
70. Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., Langmuir, V., Rugo, H. S. (2005). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23:792-799.
71. Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., Baselga, J. (2005). A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 11:3369-3376.
72. Miodonski, A., Kus, J., Olszewski, E., Tyrankiewicz, R. (1980). Scanning electron microscopic studies on blood vessels in cancer of the larynx. Arch. Otolaryngol. 106:321-332.
73. Mooteri, S., Rubin, D., Leurgans, S., Jakate, S., Drab, E., Saclarides, T. (1996). Tumor angiogenesis in primary and metastatic colorectal cancers. Dis. Colon Rectum 39:1073-1080.
74. Motzer R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., Rini, B. I. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24:16-24.
75. Mross, K., Drevs, J., Muller, M., Medinger, M., Marme, D., Hennig, J., Morgan, B., Lebwohl, D., Masson, E., Ho, Y. Y., Gunther, C., Laurent, D., Unger, C. (2002). Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur. J. Cancer 41:1291-1299.
76. Nelson, D. A., Tan, T. T., Rabson, A. B., Anderson, D., Degenhardt, K., White, E. (2004). Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 18:2095-2107.
77. Niedergethmann, M., Hildenbrand, R., Wostbrock, B., Hartel, M., Sturm, J. W., Richter, A., Post, S. (2002). High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25:122-129.
78. Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T., Alitalo, K. (2000). Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156:1499-1504.
79. Park, J. E., Keller, G. A., Ferrara, N. (1993). The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4:1317-1326.
80. Pezzella, F., Pastorino, U., Tagliabue, E., Andreola, S., Sozzi, G., Gasparini, G., Menard, S., Gatter, K. C., Harris, A. L., Fox, S., Buyse, M., Pilotti, S., Pierotti, M., Rilke, F. (1997). Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151:1417-1423.
81. Poon, R. T., Fan, S. T., Wong, J. (2001). Clinical implication of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19:1207-1225.
82. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., Hicklin, D. J. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59:5209-5218.
83. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Gore, M., Desai, A., Patnaik, A., Xiong, H. Q., Schwartz, B., O'Dwyer, P. (2005). Final findings from a phase II, placebo-controlled, randomized discontinuation trail (RDT) of sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Proceedings, Abstract Number 4544.
84. Relf, M., LeJeune, S., Scott, P. A., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., Harris, A. L. (1997). Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:963-969.
85. Renton, A., Llanos, S., Lu, X. (2003). Hypoxia induces p53 through a pathway distinct from most DNA-damaging and stress-inducing agents. Carcinogenesis 24:1177-1182.
86. Rich, J. N., Sathornsumetee, S., Keir, S. T., Kieran, M. W., Laforme, A., Kaipainen, A., McLendon, R. E., Graner, M. W., Rasheed, B. K. A., Wang, L., Reardon, D. A., Ryan, A. J., Wheeler, C., Dimery, I., Bigner, D. D., Friedman, H. S. (2005). ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res. 11:8145-8157.
87. Ryschich, E., Schmidt, J., Hammerling, G. J., Klar, E., Ganss, R. (2002). Tranformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 97:719-725.
88. Senger, D. R., Perruzzi, C. A., Feder, J., Dvorak, H. F. (1986). A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46:5629-5632.
89. Seo, Y., Baba, H., Fukuda, T., Takashima, M., Sugimachi, K. (2000). High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239-2245.
90. Sini, P., Wyder, L., Schnell, C., O'Reilly, T., Littlewood, A., Brandt, R., Hynes, N. E., Wood, J. (2005). The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res. 11:4521-4532.
91. Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Jackson, D. G., Nishikawa, S., Kubo, H., Achen, M. G. (2001). VEGF-D promotes the metastatic spread of tumor cells via lymphatics. Nature Med. 7:186-191.
92. Stadler, W. M., Kuzel, T., Shapiro, C., Sosman, J., Clark, J., Vogelzang, N. J. (1999). Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17:2541-2545.
93. Stessels, F., van den Eynden, G., van der Auwera, I., Salgado, R., van den Heuvel, E., Harris, A. L., Jackson, D. G., Colpaert, C. G., van Marck, E. A., Dirix, L. Y., Vermeulen, P. B. (2004). Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 90:1429-1436.
94. Sundberg, C., Nagy, J. A., Brown, L. F., Feng, D., Eckelhoefer, I. A., Manseau, E. J., Dvorak, A. M., Dvorak, H. F. (2001). Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am. J. Pathol. 158:1145-1160.
95. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., Ellis, L. M. (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964-3968.
96. Teicher, B. A. (1995). Angiogenesis and cancer metastases: therapeutic approaches. Crit. Rev. Oncol./Hematol. 20:9-39.
97. Teicher, B. A. (1996). A systems approach to cancer therapy. Cancer. Met. Rev. 15:247-272.
98. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92:205-216.
99. Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., Jain, R. K. (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731-3736.
100. Tonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., Hicklin, D. J. (2006). Synergistic antitumor effects of combined epidermal growth factor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12:2197-2207.
101. Tyagi, P. (2005). Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin. Lung Cancer 6:276-278.
102. Van den Eynden, G. G., Van der Auwera, I., Van Laere, S. J., Colpaert, C. G., Turley, H., Harris, A. L., van Dam, P., Dirix, L. Y., Vermeulen, P. B., van Marck, E. A. (2005). Angiogenesis and hypoxia in lymph node metastasis is predicted by the angiogenesis and hypoxia in the primary tumor in patients with breast cancer. Br. J. Cancer 93:1128-1136.
103. Vaupel, P. (2004). The role of hypoxia-induced factors in tumor progression. The Oncologist 9:10-17.
104. Vaupel, P., Kelleher, D. K., Hockel, M. (2001). Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Sem. Oncol. 28:29-35.
105. Veikkola, T., Karkkainen, M., Claesson-Welsh, L., Alitalo, K. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:203-212.
106. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S., Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., Chen, H. X., Shellito, P. C., Lauwers, G. Y., Jain, R. K. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10:145-147.
107. Williams, K. J., Telfer, B. A., Xenaki, D., Sheridan, M. R., Desbaillets, I., Peters, H. J., Honess, D., Harris, A. L., Dachs, G. U., van der Kogel, A., Stratford, I. J. (2005). Enhanced response to radiotherapy in tumors deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol. 75:89-98.
108. Winkler, F., Kozin, S. V., Tong, R. T., Chae, S. S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., Munn, L. L., Jain, R. K. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563.
109. Withers, H. R., Peters, L. J., Taylor, J. M., Owen, J. B., Morrison, W. H., Schultheiss, T. E., Keane, T., O'Sullivan, B., Van Dyk, J., Gupta, N., Wang, C. C., Jones, C. U., Doppke, K. P., Myint, S., Thompson, M., Parsons, J. T., Mendenhall, W. M., Dische, S., Aird, E. G. A., Henk, J. M., Bidmead, M. A. M., Svoboda, V., Chon, Y., Hanlon, A. L., Peters, T. L., Hanks, G. E. (1995). Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int. J. Rad. Oncol. Phys. 33:549-562.
110. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., Bohlen, P. (1998). Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17:155-161.
111. Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., Rosenberg, S. A. (2003). A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-434.
112. Yu, J. L., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., Coomber, B. L. (2001). Heterogeneous vascular dependence of tumor populations. Am. J. Pathol. 158:1325-1334.
113. Yuan F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., Jain, R. K. (1996). Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93:14765-14770.